Antimicrobial Agents and Chemotherapy · 2015 · 33 citations · 23 references
Life SciencesInfectious DiseasesMicrobiologyAntimicrobial PharmacotherapyAntimicrobial ResistanceMedical MicrobiologyAntibiotic ResistanceBacterial InfectionsMultidrug ResistanceSexually Transmitted InfectionsAntibiotic Therapy For GonorrheaAntimicrobial Resistance In GonorrheaCeftriaxone TherapyMultidrug-resistant PathogensNeisseria Gonorrhoeae Resistance
We tested the activity of ETX0914 against 187 Neisseria gonorrhoeae isolates from men with urethritis in Nanjing, China, in 2013. The MIC50, MIC90, and MIC range for ETX0914 were 0.03 μg/ml, 0.06 μg/ml, and ≤0.002 to 0.125 μg/ml, respectively. All isolates were resistant to ciprofloxacin, and 36.9% (69/187) were resistant to azithromycin. Of the isolates, 46.5% were penicillinase-producing N. gonorrhoeae (PPNG), 36% were tetracycline-resistant N. gonorrhoeae (TRNG), and 13% (24 isolates) had an MIC of 0.125 μg/ml for ceftriaxone. ETX0914 may be an effective treatment option for gonorrhea.
23
Performance standards for antimicrobial susceptibility testing
Mary Jane Ferraro · 2001 · 9.8K citations
Sexually transmitted diseases treatment guidelines (2015)
Kimberly Workowski, Gail Bolan · Reproductive Endocrinology · 2015 · 2.7K citations · Full text
Magnus Unemo, Daniel Golparian, Robert A. Nicholas et al. · Antimicrobial Agents and Chemotherapy · 2011 · 642 citations